331. Idiopathic multicentric castleman disease
30 clinical trials,   44 drugs   (DrugBank: 23 drugs),   30 drug target genes,   148 drug target pathways

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-012380-34-NL
(EUCTR)
23/03/201021/10/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
78Phase 2France;Hungary;Spain;Belgium;Germany;Netherlands;United Kingdom
2EUCTR2009-012380-34-HU
(EUCTR)
18/03/201015/12/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen Biologics BVNULLNot RecruitingFemale: yes
Male: yes
78Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain
3EUCTR2009-012380-34-DE
(EUCTR)
27/01/201015/10/2009A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease Multicentric Castleman's disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
75United Kingdom;France;Hungary;Spain;Belgium;Netherlands;Germany
4EUCTR2009-012380-34-BE
(EUCTR)
26/01/201005/10/2009A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease Multicentric Castleman's disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
78Phase 2Hong Kong;United States;Taiwan;Israel;Russian Federation;United Kingdom;India;France;Egypt;Hungary;Canada;Malaysia;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;Norway;New Zealand;China;Korea, Republic of;Spain
5EUCTR2009-012380-34-FR
(EUCTR)
21/01/201016/10/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
75Phase 2France;Hungary;Spain;Belgium;Netherlands;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2009-012380-34-ES
(EUCTR)
21/12/200908/10/2009Estudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDiseaseEstudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDisease enfermedad de Castleman multicéntrica
MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
75Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain